Wolfe Research analyst Kalpit Patel initiated coverage of Oric Pharmaceuticals (ORIC) with a Peer Perform rating and no price target The firm highlights the baseline imbalance in Pfizer’s (PFE) mevro study and thinks that the magnitude of benefit may be overstated with the PRC2 inhibitor drug class.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals price target raised to $16 from $12 at Citi
- Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
- Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target
- Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright
- Promising Developments and Strong Cash Position Justify Buy Rating for ORIC Pharmaceuticals